2026

Clinical scores to predict toxicities and outcomes in patients with multiple myeloma undergoing bispecific T-cell engager therapy
Frenking J, Riedhammer C, Hielscher T, Schaefers C, Leypoldt L, Harzer M, Sedloev D, Landrin V, Kehl N, Friedrich M, Zhou X, Steinhardt M, Weis P, Mersi J, Waldschmidt J, Weinhold N, Kortüm K, Müller-Tidow C, Einsele H, Sauer S, Weisel K, Richardson T, Teipel R, Rasche L, Raab M
BLOOD CANCER DISCOV. 2026.

2025

Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement
Steinhardt M, Schaefers C, Leypoldt L, Blau I, Harzer M, Zhou X, Riedhammer C, Kamili A, Kosch R, Topp L, Molwitz I, Gross-Fengels N, Melzer Y, Artzenroth J, Al-Bazaz M, Alsdorf W, Topp M, Duell J, Mersi J, Waldschmidt J, Bokemeyer C, Einsele H, Kortüm K, Weisel K, Rasche L
BLOOD CANCER J. 2025;15(1):126.

Correction: Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement
Steinhardt M, Schaefers C, Leypoldt L, Blau I, Harzer M, Zhou X, Riedhammer C, Kamili A, Kosch R, Topp L, Molwitz I, Gross-Fengels N, Melzer Y, Artzenroth J, Al-Bazaz M, Alsdorf W, Topp M, Duell J, Mersi J, Waldschmidt J, Bokemeyer C, Einsele H, Kortüm K, Weisel K, Rasche L
BLOOD CANCER J. 2025;15(1):.

Letzte Aktualisierung aus dem FIS: 24.02.2026 - 05:13 Uhr